You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥(01672.HK)與蘇州康寧傑瑞簽署全球獨家開發協議
阿思達克 11-08 09:37
歌禮制藥(01672.HK)公佈,全資子公司與蘇州康寧傑瑞已簽署ASC22(恩沃利單抗)於大中華區以外治療包括乙型肝炎在內的所有病毒性疾病的全球獨家開發協議。ASC22(又稱KN035)是一款同類第一可皮下注射的PD-L1抗體藥物。 根據協議條款,蘇州康寧傑瑞授予歌禮在大中華區以外開發及商業化ASC22的全球獨家權益,授權適應症爲包括乙型肝炎在內的所有病毒性疾病。歌禮將向蘇州康寧傑瑞支付現金首付款,蘇州康寧傑瑞將有權從歌禮獲得開發、註冊和商業化裏程碑付款以及約15%至約20%的梯度銷售額分成。蘇州康寧傑瑞將負責爲歌禮生產用於病毒性疾病臨牀研究和商業化所需的ASC22。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account